Dual Inhibition of Human Type 4 Phosphodiesterase Isostates by (R,R)-(±)-Methyl 3-Acetyl-4-[3-(cyclopentyloxy)-4-methoxyphenyl]-3- methyl-1-pyrrolidinecarboxylate

Purified recombinant human type 4 phosphodiesterase B2B (HSPDE4B2B) exists in both a low- and a high-affinity state that bind (R)-rolipram with K d's of ca. 500 and 1 nM, respectively [Rocque, W. J., Tian, G., Wiseman, J. S., Holmes, W. D., Thompson, I. Z., Willard, D. H., Patel, I. R., Wisely,...

Full description

Saved in:

Bibliographic Details
Published in:	Biochemistry (Easton) Vol. 37; no. 19; pp. 6894 - 6904
Main Authors:	Tian, Gaochao, Rocque, Warren J, Wiseman, Jeffrey S, Thompson, Irene Z, Holmes, William D, Domanico, Paul L, Stafford, Jeffrey A, Feldman, Paul L, Luther, Michael A
Format:	Journal Article
Language:	English
Published:	United States American Chemical Society 12-05-1998
Subjects:	3',5'-Cyclic-AMP Phosphodiesterases - antagonists & inhibitors 3',5'-Cyclic-AMP Phosphodiesterases - genetics 3',5'-Cyclic-AMP Phosphodiesterases - metabolism Binding, Competitive - drug effects Binding, Competitive - genetics Cyclic Nucleotide Phosphodiesterases, Type 4 Humans Isoenzymes - antagonists & inhibitors Isoenzymes - genetics Isoenzymes - metabolism Mutagenesis, Site-Directed Phosphodiesterase Inhibitors - metabolism Phosphodiesterase Inhibitors - pharmacology Pyrrolidines - metabolism Pyrrolidines - pharmacology Pyrrolidinones - metabolism Pyrrolidinones - pharmacology Rolipram Sequence Deletion
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Purified recombinant human type 4 phosphodiesterase B2B (HSPDE4B2B) exists in both a low- and a high-affinity state that bind (R)-rolipram with K d's of ca. 500 and 1 nM, respectively [Rocque, W. J., Tian, G., Wiseman, J. S., Holmes, W. D., Thompson, I. Z., Willard, D. H., Patel, I. R., Wisely, G. B., Clay, W. C., Kadwell, S. H., Hoffman, C. R., and Luther, M. A. (1997) Biochemistry 36, 14250−14261]. Since the tissue distribution of the two isostates may be significantly different, development of inhibitors that effectively inhibit both forms may be advantageous pharmacologically. In this study, enzyme inhibition and binding of HSPDE4B2B by (R,R)-(±)-methyl 3-acetyl-4-[3-(cyclopentyloxy)-4-methoxyphenyl]-3-methyl-1-pyrrolidinecarboxylate (1), a novel inhibitor of phosphodiesterase 4 (PDE 4), were investigated. Binding experiments demonstrated high-affinity binding of 1 to HSPDE4B2B with a stoichiometry of 1:1. Inhibition of PDE activity showed only a single transition with an observed K i similar to the apparent K d determined by the binding experiments. Deletional mutants of HSPDE4B2B, which have been shown to bind (R)-rolipram with low affinity, were shown to interact with 1 with high affinity, indistinguishable from the results obtained with the full-length enzyme. Bound 1 was completely displaced by (R)-rolipram, and the displacement showed a biphasic transition that resembles the biphasic inhibition of HSPDE4B2B by (R)-rolipram. Theoretical analysis of the two transitions exemplified in the interaction of (R)-rolipram with HSPDE4B2B indicated that the two isostates were nonexchangeable. Phosphorylation at serines 487 and 489 on HSPDE4B2B had no effect on the stoichiometry of binding, the affinity for binding, or the inhibition of the enzyme by 1. These data further illustrate the presence of two isostates in PDE 4 as shown previously for (R)-rolipram binding and inhibition. In contrast to (R)-rolipram, where only one of the two isostates of PDE 4 binds with high affinity, 1 is a potent, dual inhibitor of both of the isostates of PDE 4. Kinetic and thermodynamic models describing the interactions between the nonexchangeable isostates of PDE 4 and its ligands are discussed.
Bibliography:	ark:/67375/TPS-1C8T4KB8-V istex:B0A82251D6883BDE9C8A03813928FAC4884B23B8
ISSN:	0006-2960 1520-4995
DOI:	10.1021/bi972700v